Ampio Pharmaceuticals, Inc. (AMPE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2010 |
| Open | 0.1960 |
| Bid | 0.1620 x 1100 |
| Ask | 0.1725 x 1000 |
| Day's Range | 0.1784 - 0.2070 |
| 52 Week Range | 0.1500 - 1.8300 |
| Volume | |
| Avg. Volume | 4,010,285 |
| Market Cap | 40.52M |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0790 |
| Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- PR Newswire
Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.
- Benzinga
Ampio's Independent Committee Launches Investigation Related To AP-013 Trial
Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of independent legal counsel. FDA has communicated to Ampio that it does not consider data from AP-013 to be sufficient to demonstrate efficacy as a second pivotal trial for Ampion. Further analysis suggests that data from AP-013 will not be sufficient to support regulatory approval in the US or other count
- PR Newswire
Ampio Pharmaceuticals Reports First-Quarter Financial Results
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results for the first quarter ended March 31, 2022.
